ORIC appoints Steven Hoerter as director; Peter Svennilson resigns from board

Oric Pharmaceuticals, Inc.

Steven L. Hoerter, CEO of Deciphera Pharmaceuticals, appointed as Class II director effective Aug 13, 2021; will serve on Audit Committee.
Peter Svennilson resigned voluntarily as part of planned reduction of public board commitments; had served over six years since TCG's founding investment.
New director Hoerter receives annual retainer of $35,000 plus $7,500 for Audit Committee; granted option for 33,250 shares vesting monthly over 3 years.
Lease amendment expands facility by ~340 sq ft, extends term to May 2028, and landlord contributes $1,514,835 toward improvements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.